A Small Molecule Approach to Degrade RAS With EGFR Repression Is a Potential Therapy for KRAS Mutation-Driven Colorectal Cancer Resistance to Cetuximab

Experimental and Molecular Medicine - United States
doi 10.1038/s12276-018-0182-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Emergence of KRAS Mutations and Acquired Resistance to Anti-Egfr Therapy in Colorectal Cancer

Nature
Multidisciplinary
2012English

Mechanism of Resistance to Cetuximab Therapy in Colorectal Cancer

mAbs
AllergyImmunology
2012English

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy

Cancers
Cancer ResearchOncology
2020English

GC1118, a Novel Anti-Egfr Antibody, Has Potent KRAS Mutation-Independent Antitumor Activity Compared With Cetuximab in Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2019English

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-Line Cetuximab and Irinotecan

JAMA Oncology
Cancer ResearchOncology
2019English

Nuclear EGFR Contributes to Acquired Resistance to Cetuximab

Oncogene
Cancer ResearchGeneticsMolecular Biology
2009English

Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors

Cancer Cell
Cancer ResearchOncologyCell Biology
2011English

EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment

JCO Precision Oncology
Cancer ResearchOncology
2018English

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy